This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A special advisory committee of physicians on aminopyrine and dipyrone has been named by the Food and Drug Administration to provide expert medical opinion regarding these two drugs. Reports of blood disorders, some of which have been fatal, led to the appointment of the committee, FDA said.Aminopyrine and dipyrone are closely related analgesic and antipyretic drugs which have been limited to sales by prescription for many years. Aminopyrine-containing drugs have in the past been linked to blood disorders including agranulocytosis with a number of fatalities largely in Europe, FDA said. Dipyrone-containing drugs have recently been more widely used in the US than aminopyrine.Joseph F. Sadusk, Jr., MD, FDA medical director, said that since 1959, 40 reports of blood dyscrasias associated with dipyrone ingestion, with 13 fatalities, have been collected by the American Medical Association. The first fatality from dipyrone agranulocytosis was reported in 1935, the agency
WASHINGTON NEWS. JAMA. 1964;190(1):A15-A16. doi:10.1001/jama.1964.03070140101043